Drug Profile
Nevanimibe - Millendo Therapeutics
Alternative Names: ATR-101Latest Information Update: 15 Jun 2021
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Millendo Therapeutics
- Class Antineoplastics; Methylamines; Phenols; Small molecules; Urea compounds
- Mechanism of Action Acetyl-CoA C-acetyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adrenocortical carcinoma; Congenital adrenal hyperplasia; Cushing syndrome
Most Recent Events
- 30 Apr 2021 Nevanimibe is no longer licensed to Millendo Therapeutics worldwide
- 14 Jul 2020 Discontinued - Phase-I for Adrenocortical carcinoma (Late-stage disease) in USA, Germany (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)
- 14 Jul 2020 Discontinued - Phase-II for Congenital adrenal hyperplasia (In the elderly, Treatment-experienced, In adults) in Czech Republic, Israel, France, Brazil, Spain (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)